Taking certain cholesterol drugs called evolocumab or alirocumab might lower the chance of having a stroke, whether you've already had heart problems or not.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
Taking certain cholesterol drugs called evolocumab or alirocumab might lower the chance of having a stroke, whether you've already had heart problems or not.
See the technical phrasing
Treatment with the PCSK9 inhibitors evolocumab or alirocumab is associated with a reduced risk of stroke in both individuals with prior cardiovascular disease (secondary prevention) and those without (primary prevention), with reported relative risks of 0.703 and 0.733 respectively, indicating a potential protective effect against cerebrovascular events across different risk groups.
What the research says
Supports
1 study
Study: Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies